SARomics Biostructures is based in Lund, Sweden, conveniently located in the heart of Medicon Valley, one of Europe’s strongest biotech clusters. The company was founded in 2006 and is now the No 1 provider of protein 3D structure determination and structure-based drug discovery services in Scandinavia with access to world leading X-ray facilities in the MAX IV laboratory. As well as offering a range of structural biology services to international clients, SARomics is engaged in its own drug discovery programmes against selected kinases and epigenetic targets.
Dr. Björn Walse, co-founder and CEO of SARomics Biostructures AB has over 20 years of drug discovery and research management experience in the biotech community. Prior to establishing SARomics Dr. Walse served as head of structural chemistry at Active Biotech where he was responsible for the build-up of their structural chemistry platform. At Active Biotech he also participated in the molecular design of a biopharmaceutical therapeutic currently in phase III trials for an oncology indication. Prior to this Dr. Walse performed postdoctoral research at the University of California, Berkeley. Dr. Walse received his Doctorate in physical chemistry from Lund University and his M.Sc. in Chemical Engineering from Lund Institute of Technology.